FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Forbes William P
2. Issuer Name and Ticker or Trading Symbol

Trevi Therapeutics, Inc. [ TRVI ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Development Officer
(Last)          (First)          (Middle)

C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 14TH FLOOR
3. Date of Earliest Transaction (MM/DD/YYYY)

2/11/2022
(Street)

NEW HAVEN, CT 06510
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

2/15/2022 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) $0.511 2/11/2022  A   137500     (1)2/10/2032 Common Stock 137500 $0.00 137500 D (2) 

Explanation of Responses:
(1) This option was granted on February 11, 2022. The 137,500 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 11, 2023 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.
(2) This amendment to the Form 4 originally filed for the reporting person on February 15, 2022 is being filed solely to attach the power of attorney exhibit that was inadvertently excluded from the original filing.

Remarks:
Exhibit Index: 24 Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Forbes William P
C/O TREVI THERAPEUTICS, INC.
195 CHURCH STREET, 14TH FLOOR
NEW HAVEN, CT 06510


Chief Development Officer

Signatures
/s/ Christopher Galletta, attorney-in-fact7/1/2022
**Signature of Reporting PersonDate


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Trevi Therapeutics (NASDAQ:TRVI)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Trevi Therapeutics Charts.
Trevi Therapeutics (NASDAQ:TRVI)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Trevi Therapeutics Charts.